The trajectory of Sildenafil presents a complex picture for shareholders. While the initial launch generated substantial gains, the end of its intellectual property protection opened the floodgates to cheaper versions, dramatically eroding sales. This creates a specific risk for drug manufacturers banking on related blockbuster medications, suggest

The story of Viagra, and its creator copyright, presents a complex case study for investors. At first a blockbuster drug, producing billions in income, its patent expiration created a deluge of knock-off medications, significantly diminishing its market share . While some pharmaceutical companies may attempt to capitalize on related treatments , th